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Abstract A panel of cytokine-secreting RM-9 prostate
cancer cells were tested as whole cell vaccines to determine
their capacity to evoke an anti-prostate cancer immune
response. In our model, vaccines secreting mGM-CSF or
mIL-7 resulted in the highest increase in circulating T lym-
phocytes after vaccination, prolonged survival and, in a
proportion of animals, tumor-free survival. Anti-tumor
eVects were more evident after a subcutaneous RM-9 chal-
lenge than after an intraprostatic challenge. However, when
the RM-9/mGM-CSF cell line was used as intraprostatic
tumor challenge, protection after RM-9/mIL-7 vaccination
was restored.
Keywords Immunotherapy · Whole cell vaccine · 
Cytokines · Prostate cancer · MPR-model
Introduction
Prostate cancer is currently the most commonly diagnosed
non-cutaneous malignancy in American and European men.
Each year, about 600,000 new cases are diagnosed and
about 200,000 men die worldwide, turning prostate cancer
into a major public health problem [11]. Treatment of early
stage (localized) prostate cancer may involve radical
prostatectomy, active surveillance, radiation therapy and
hormonal therapy. In case cancer has spread beyond the
prostate, treatment options are limited. Palliative treatment
for metastized prostate cancer is mainly focused on extend-
ing life and relief of symptoms. Therefore, new therapeutic
modalities that speciWcally eradicate metastatic disease are
needed.
The theoretical concept of a speciWc immune response
against cancer is quite old and dates back to the nineteenth
century [18, 37]. In practice it has been proven very diY-
cult to use immunotherapy against cancer. Tumors appear
to be poorly immunogenic and often escape the hosts’
immune response because they may lack both major histo-
compatibility complex (MHC) and co-stimulatory mole-
cules [26]. Furthermore, regulatory T lymphocytes
(CD25+) are abundant in blood and tumor of cancer
patients, which actively inhibits the proliferation of cancer-
speciWc cytotoxic T lymphocytes [25, 33]. Over the years,
several strategies have been explored that tried to overcome
these escape mechanisms such as dendritic cell based
immunotherapy [27], T lymphocyte based adoptive therapy
[8], and vaccination therapy [5, 30, 32]. The use of autolo-
gous cancer cells as vaccines to augment tumor immunity
has been explored, but the responses observed generally
have been only partial and shorted-lived. Because of the
poor immunogenicity of cancer cells, it is diYcult to evoke
the desired anti-cancer immune responses by vaccination
only. Therefore, administration of cytokines could enhance
the host’s immune responses during vaccination.
Cytokines are secreted low molecular weight proteins
that have a short half-life and serve as local mediators of
cell–cell interactions. They include, among other molecules,
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stimulating factors (CSFs). When cytokines are used as a
medical drug, systemic administration at very high concen-
trations is necessary to achieve biologically meaningful
concentrations at the target site. These high concentrations
are associated with systemic toxicity, which limits their use
and eYcacy [14]. To bypass the toxic eVects of systemic
administration and to reach a biological meaningful con-
centration for inducing an optimal immune response, tumor
cells were genetically modiWed to secrete cytokines locally.
Such genetically modiWed tumor cells were rejected by the
host with minimal side eVects [4, 10, 16, 17, 35], whereas
unmodiWed cells were not rejected [17]. The observed anti-
tumor responses involved recruitment of CD8+ T lympho-
cytes as well as recruitment of CD4+ T lymphocytes. Fur-
thermore, several studies indicate that cytokine-secreting
tumor cells increase systemic immunity as well, since mice
vaccinated with cytokine-producing tumor cells reject a
subsequent challenge of unmodiWed tumor cells, and in
some cases, a preexisting tumor [7, 17, 22]. Since most of
these studies have been carried out for diVerent types of
cancer models, cytokine-producing vaccines could also be
of interest for rejection of prostate tumor cells.
In the present study, a panel of cytokine-producing
whole cell vaccines (mIL-2, mIL-4, mIL-7, mGM-CSF and
mCD40L) was constructed and analyzed for the induction
of additional protection compared to a non-cytokine-pro-
ducing cell vaccine against prostate cancer in an immune-
competent mouse prostate cancer model.
Materials and methods
Mouse prostate reconstitution model
The mouse prostate reconstitution model [15, 19] was
kindly provided by Dr. T.C. Thompson. This model con-
sists of several mouse prostate cancer cell lines that were
derived from urogenital sinus cells from p53 knock-out
C57bl/6 mice. These cells were transformed by retroviral
transduction with the ras- and myc-oncogenes.
The RM-9 cell line of this model was cultured in low-
glucose Dulbecco’s modiWed Eagles’s medium (DMEM;
Invitrogen, Breda, The Netherlands) supplemented 1:1 with
Ham’s F12 (Biowhittaker, Cambrex, Verviers, Belgium),
10% fetal calf serum (FCS; Hyclone, Etten-Leur, The Neth-
erlands), 100 U/ml penicillin and 100 g/ml streptomycin
(Biowhittaker). Cells were grown at 37°C in a humidiWed
atmosphere of 5% CO2 in air and passaged twice a week.
Male C57bl/6 mice (6–12 weeks old) were purchased
from Charles River Laboratories (St. Germain sur l’Arbre-
sle, France), housed in individually ventilated cages (IVCs)
and allowed to acclimatize for 1 week. Mouse chow and
water were given ad libitum. Animal experiments were per-
formed under the national Experiments on Animals Act that
serves the implementation of “Guidelines on the protection
of experimental animals” by the Council of Europe (1986),
Directive 86/609/EC, and only after a positive recommen-
dation by the Animal Experiments Committee. No alterna-
tives (in relation to Replacement, Reduction or ReWnement)
were available.
Immunisation and tumor challenge strategy
The RM-9 cell line was retrovirally transduced to produce
the immunostimulatory cytokines mIL-2, mIL-4, mIL-7,
mGM-CSF and mCD40L [34]. Cytokine expression per
one million of transfected cells per 24 h was determined to
be 109 ng (mIL-2), 233 ng (mIL-4), 29 ng (mIL-7) and
397 ng (mGM-CSF). Expression of mCD40L was con-
Wrmed by FACS analysis.
Cells were harvested by trypsinisation, washed twice with
PBS, resuspended in PBS at a density of 1 £ 107 cells/ml,
and -irradiated at 75 Gy. Vaccination was performed once a
week for three consecutive weeks by subcutaneous injection
of 1 £ 106 -irradiated cells. One week after the Wnal vacci-
nation, a challenge was administered either orthotopically in
the dorsolateral prostate (5 £ 104 cells in 20 l PBS) under
anesthesia [29] or subcutaneously (1 £ 105 cells in 100 l
PBS). Orthotopic growth was monitored by transrectal ultra-
sonography under anesthesia with isoXuraan/O2 [21] and
subcutaneous tumor growth was monitored by calliper mea-
surements. Mice were killed when suVering from tumor bur-
den, or when tumors exceeded 1,500 mg for subcutaneous
tumors or 1,000 mg for orthotopic tumors.
Flow cytometry
Blood was collected in heparine-containing tubes (Sarstedt,
Germany) through retro-orbital puncture under anesthesia
with isoXuraan/O2, incubated for 1 h on ice with combina-
tions of anti-mCD3-PE, anti-mCD4-PE-Cy5 and anti-
mCD8-FITC, antibodies (BD Biosciences, Breda, The
Netherlands), washed twice with PBS, disposed of erythro-
cytes with FACS™ lysis solution (BD Biosciences, Breda,
The Netherlands), washed with PBS and Wxed with 1%
paraformaldehyde (Fluka Chemie GmBH, Buchs, Germany).
FACS measurements were performed on a FACScan
(BD Biosciences) and analyzed by CellQuest™ Pro, version
4.0.2 (BD Biosciences).
Histology
Tumors were snap-frozen in liquid nitrogen and stored at
¡80°C. Frozen sections (4–5 m) were Wxed in acetone
and stained with anti-mCD4+, anti-mCD8+, anti-mCD11+123
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body was detected using the anti-rat Ig HRP detection kit
(BD Pharmingen) and counterstained with heamatoxilin
and eosin. The sections were scored three times for inWl-
trated areas, which were represented as a percentage of the
total vital tumor tissue.
Statistical analyses
Statistical analyses of survival and FACS data were per-
formed with the Mann-Whitney U-test and the Student T-
test, respectively, using SPSS version 11.0.1 (2001). DiVer-
ences were considered signiWcant when P · 0.05.
Results
Prolonged survival with IL-7 or GM-CSF-secreting 
vaccines
The panel of cytokine-producing RM-9 lines, together with
the parental RM-9 and PBS as controls, were analyzed as
vaccines. Seven groups of nine C57bl/6 mice were vacci-
nated and subcutaneously challenged with RM-9 cells
(Fig. 1). The median survival after PBS vaccination was
13.1 § 1.9 days. The RM-9 vaccinated group showed a
signiWcantly (P = 0.0004) prolonged survival of 34.0 §
8.2 days compared to the PBS control. The cytokine-
producing vaccines were compared to the RM-9 control
group. Survival after RM-9/mIL-2 and RM-9/mCD40L
vaccination was comparable to survival of RM-9 vacci-
nated mice (29.9 § 4.4 days and 29.7 § 5.8 days, respec-
tively). Survival after RM-9/mIL-4 vaccination showed a
decrease in life expectancy (21.0 § 6.0 days). However,
when mice were vaccinated with RM-9/mGM-CSF or RM-
9/mIL-7 also tumor-free survival was observed. Vaccina-
tion with RM-9/mGM-CSF resulted in the tumor-free
survival of three out of nine mice and the median life-time
of the non-survivors was 24.6 § 2.2 days. RM-9/mIL-7
vaccination resulted in the survival of four out of nine mice,
with and median life-time of non-surviving mice of
34.4 § 7.1 days. Only the survival of the mice vaccinated
with RM-9/mIL-7 was signiWcant compared to the RM-9
control group (P = 0.025).
Increased CD4+ and CD8+ T lymphocyte responses 
after vaccination
To gain insight into the mechanisms of action of the diVer-
ent vaccines, T cell responses were analyzed. Blood was
taken before and after vaccination (but before challenge
administration), and CD4+ and CD8+ T lymphocyte popula-
tion were analyzed (Fig. 2).
PBS and RM-9 vaccination did not induce (increase in
circulating) CD4+ and CD8+ T-lymphocyte populations.
However, all cytokine-producing vaccines induced signiW-
cant increases in circulating CD4+ and CD8+ T lymphocyte
populations. Moreover, the most eVective vaccines, RM-9/
mGM-CSF and RM-9/mIL-7, that resulted in tumor-free
survival, showed the highest CD4+ and CD8+ T lymphocyte
counts. Furthermore, survivors and non-survivors were
compared in CD4+ and CD8+ T lymphocyte responses. The
survivors of the RM-9/mIL-7 vaccination group showed a
signiWcant lower CD8+ T lymphocyte count compared to
the non-survivors (P = 0.031). Survivors of the RM-9/
mGM-CSF vaccination group showed a signiWcant higher
CD4+ T lymphocyte count (P = 0.046) (data not shown).
To determine whether systemic CD4+ and CD8+
lymphocyte responses were reXected by the inWltrate of
end-point tumor tissues, immune histochemistry was per-
formed. Necrosis (HE-staining), T lymphocytes (CD4+,
CD8+), B lymphocytes (CD19+) as well as myelocytes and
NK cells (CD11b+) were determined (Fig. 3). All vaccina-
tion groups showed to some degree necrotic areas in the
tumor. The largest necrotic areas were observed in the
groups vaccinated with RM-9/mIL-7, RM-9/mGM-CSF
and RM-9/CD40L.
Fig. 1 Survival of vaccinated mice after subcutaneous challenge with
RM-9 cells. Mice were vaccinated with 1 £ 106 -irradiated cells or
PBS. Vaccines were administered once a week for three consecutive
weeks, followed by a challenge of RM-9 cells in the fourth week.
Tumor size was measured in time and survival determined (* P < 0.05
compared to the RM-9 vaccinated group)


























PBS 13.1 ± 1.9 0/9
 RM-9 34.0 ± 8.2 0/8
RM-9/mIL-2 29.9 ± 4.4 0/9
 RM-9/mIL-4 21.0 ± 6.0 0/9
RM-9/mIL-7 34.4 ± 7.1 4/9 * 
RM-9/mGM-CSF 24.6 ± 2.2 3/9
 RM-9/mCD40L 29.7 ± 5.8 0/9
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groups throughout the tumor. T lymphocytes were mostly
located at the rim of the tumor. Mice vaccinated with RM-
9, RM-9/mIL-2, RM-9/mIL-7, RM-9/mGM-CSF or RM-9/
mCD40L showed the highest (»5%) CD4+ T lymphocyte
inWltration. Cytotoxic T lymphocytes (CD8+) were mostly
observed (»5%) in tumors of mice vaccinated with RM-9/
mIL-2, RM-9/mIL-7, RM-9/mGM-CSF or RM-9/mCD40L.
CD19+ B lymphocytes were only observed in tumors of
mice vaccinated with RM-9/mIL-7.
Survival diVerence between subcutaneous 
and intraprostatic tumor challenge
Next, survival was determined after an intraprostatic chal-
lenge, which represents a more natural model for prostate
cancer. Seven groups (n = 4) of mice were vaccinated with
the cytokine-producing cell lines, the parental RM-9 line or
PBS control, and challenged intraprostatically with the
parental RM-9 cell line (Fig. 4a). No signiWcant diVerences
could be observed between the cytokine-producing vac-
cines and the RM-9 control.
The observed prolonged survival of vaccinated mice
against the subcutaneous tumor challenge of the RM-9
parental cell line was no longer observed when the same
tumor challenge was administered intraprostatically. This
unexpected outcome against the intraprostatic challenge
might be due to diVerences in immune surveillance
between the skin and the prostate. Therefore, a study was
designed using the RM-9/mGM-CSF cell line as intrapros-
tatic challenge. Such a tumor challenge might recruit anti-
gen-presenting cells (APCs) into the prostate and increase
immune surveillance. Four groups (n = 4) of mice were
vaccinated with PBS or RM-9/mIL-7 cells and intrapro-
statically challenged with either parental RM-9 cells or
RM-9/mGM-CSF cells (Fig. 4b). In the PBS vaccinated
groups, challenged with either the parental RM-9 cell line
or the RM-9/mGM-CSF cell line, no diVerence in survival
was observed. Also, no diVerence in survival was
observed when the PBS and RM-9/mIL-7 vaccination
groups were challenged with the parental RM-9 cell line.
However, enhanced survival and one tumor-free survivor
were observed in mice vaccinated with RM-9/mIL-7 and
challenged with RM-9/mGM-CSF (P < 0.05) compared
to PBS vaccination followed by the RM-9/mGM-CSF
challenge.
To determine if the observed prolonged survival of the
RM-9/mIL-7 vaccinated and RM-9/mGM-CSF challenged
mice was due to increased recruitment of immune cells,
CD4+, CD8+, CD11b+ and CD19+ cells were determined in
end-point tumors (Fig. 4c). The mGM-CSF-producing
tumor challenge resulted in increased numbers of CD11b+
cells, both after PBS or RM-9/mIL-7 vaccination. RM-9/
mIL-7 vaccination resulted in higher numbers of T lympho-
cytes compared to the PBS vaccinated mice. The CD4+ T
lymphocytes were mostly located at the rim of the RM-9
tumor, whereas in RM-9/mGM-CSF tumor tissue these
cells were spread throughout the tumor.
Discussion
In the present study, a panel of cytokine-producing RM-9
cell lines was tested as vaccines. This panel of cytokines
(IL-2, IL-4, IL-7, GM-CSF and CD40L) was chosen for
their capabilities to induce inXammation at the vaccination
site via tumor antigen uptake by antigen presenting cells
(APC), presentation by MHC molecules, and co stimulation
of T cells in local lymph nodes (also known as “antigen
cross priming”).
Mice vaccinated with either the RM-9/mGM-CSF or the
RM-9/mIL-7 cell line and subcutaneously challenged with
the parental RM-9 cell line showed increased systemic
CD4+ and CD8+ lymphocyte counts and tumor-free sur-
vival. This vaccination eVect was not observed when mice
Fig. 2 The systemic response of CD3+/CD4+ (a) and CD3+/CD8+ (b)
lymphocytes at T = 0 (before vaccination) and T = 1 (after vaccination,
before challenge administration). Blood was taken via retro-orbital
puncture, stained for CD3+/CD4+ or CD3+/CD8+ lymphocytes and
were quantiWed by FACS analysis. The mean cell count per 10,000
cells § SEM is depicted (* P < 0.05 compared to the RM-9 vaccinated
group)123
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intraprostatic challenge by the RM-9/mGM-CSF cell line
restored the RM-9/mIL-7 vaccination eVects.
The observed survival from a subcutaneous challenge
and the immune response after RM-9/mGM-CSF vaccina-
tion were considered to be an additional eVect of the
secreted mGM-CSF during vaccination compared to the
RM-9 control vaccination. The immunostimulatory cyto-
kine mGM-CSF recruits and stimulates antigen-presenting
cells (APCs). When secreted during vaccination, APCs are
recruited to the vaccination site. After contact of APCs with
the RM-9/mGM-CSF cells, the APCs migrate to the lymph
node where digested epitopes are presented to T lympho-
cytes, leading to antigen-speciWc activation of the T lym-
phocyte populations responsible for the desired anti-tumor
immune responses. Analysis of blood from mice vaccinated
with RM-9/mGM-CSF showed a signiWcant higher increase
of T lymphocytes compared to the control RM-9 vaccina-
tion, which might have been beneWcial for tumor survival.
Earlier reports on tumor cell-based vaccines, in which GM-
CSF secreting, irradiated tumor cells were used to generate
an anti-tumor response against melanoma, cervical cancer
or prostate cancer report a GM-CSF-mediated increase in T
lymphocytes populations [5, 7, 30, 32]. With regard to the
increased circulation of T lymphocytes after RM-9/mGM-
CSF vaccination it was expected that this would have an
eVect on the survival of these mice. Even though the pro-
longed survival after RM-9/mGM-CSF vaccinated mice
was not signiWcantly diVerent compared to the RM-9 con-
trol vacation, three out of nine mice did not develop any
tumor up to 125 days after tumor challenge administration.
The tumors of mice that did not survive the challenge were
screened for necrotic areas and immunological inWltration.
Even though both CD4+ T lymphocytes and CD11+b cells
were detected in the end-point tumors of the RM-9 vaccina-
tion control group, the non-surviving RM-9/mGM-CSF
mice also showed larger necrotic areas and an increased
inWltration of CD8+ T lymphocytes. This would suggest
that despite the fact that these mice did not survive the
tumor challenge, the mGM-CSF secretion during vaccina-
tion was capable of boosting the anti-tumor response. An
explanation for the diVerence between survivors and non-
survivors within the RM-9/mGM-CSF group, based on cir-
culating CD4+ and CD8+ T lymphocytes after vaccination,
might be the signiWcant increase in CD4+ T-lymphocytes
that was detected in the survivors. A beneWcial relation
between GM-CSF and survival has also been reported in
studies on HIV. In these studies GM-CSF was administered
to HIV-infected patients, which eventually led to increased
CD4+ T lymphocyte counts [1, 20].
Fig. 3 Immune histochemistry 
of endpoint tumors 
(tumor ¸ 1,500 mg) of the 
diVerent vaccination groups. 
Frozen sections were stained 
with HE or for CD4+, CD8+, 
CD11b+ or CD19+ cell markers 
and scored three times on three 
diVerent days123
378 Cancer Immunol Immunother (2009) 58:373–381Fig. 4 Survival of vaccinated C57bl/6 mice after intraprostatic chal-
lenge. a C57bl/6 mice were subcutaneously vaccinated once a week for
three consecutive weeks, followed by an intraprostatic RM-9 challenge
in the fourth week and monitored for tumor development via transrec-
tal ultrasonography (* P < 0.05 compared to the RM-9 vaccinated
mice). b C57bl/6 mice were s.c. vaccinated with PBS or RM-9/mIL-7
once a week for three consecutive weeks, followed with an intrapros-
tatic challenge with RM-9 or RM-9/mGM-CSF in the fourth week and
was monitored for tumor development via transrectal ultrasonography
and survival was determined (* P < 0.05 compared to RM-9/mIL-7
vaccinated mice challenged with an RM-9 challenge). c Immune histo-
chemistry of endpoint tumors (tumor ¸ 1,000 mg) of mice challenged
intraprostatically with either RM-9 or RM-9/mGM-CSF after vaccina-
tion with PBS or RM-9/mIL-7. Frozen sections were stained for HE or
for CD4+, CD8+, CD11b+ or CD19+ cell markers and scored three
times on three diVerent days


















PBS 12.4 ± 0.0 0/3 
RM-9 16.6 ± 1.6 0/3 
RM-9/mIL-2 16.6 ± 0.8 0/4 
 RM-9/mIL-4 14.0 ± 0.3 0/3 
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RM-9/mGM-CSF 16.9 ± 2.9 0/4 
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PBS ~ RM-9/mGM-CSF 15.0 ± 0.8 0/4
 RM-9/mIL-7 ~ RM-9 17.6 ± 1.0 0/4




Cancer Immunol Immunother (2009) 58:373–381 379Besides the RM-9/mGM-CSF vaccine, survival from the
subcutaneous tumor challenge was also determined in the
RM-9/mIL-7 vaccination group. IL-7, known as a hemato-
poeitic growth factor, is important for the development and
survival of T lymphocytes, involved in the expansion of T
cell numbers and has the ability to increase their prolifera-
tion even in the absence of activation [3, 13, 36]. In our
study this eVect was observed in mice that were vaccinated
with the mIL-7 producing vaccine. The detected increase of
circulating T lymphocytes was found after vaccination, this
increase was even the highest increase after vaccination
compared to all the other tested vaccines. It was hypothe-
sized that epitopes of the RM-9/mIL-7 vaccine were picked
up by the already present APCs at the vaccination site,
which were presented to the lymphocytes in the lymph
nodes. But also lymphocytes present at the vaccination site
might be stimulated in development and survival due to the
secreted mIL-7. With the knowledge of the increased circu-
lation of T lymphocytes after vaccination, a prolonged or
even tumor-free survival was expected of the mice vacci-
nated with RM-9/mIL-7. This expectation was conWrmed
with a signiWcant longer survival compared to the RM-9
vaccination control group, and four out of the 9 mice
remained tumor-free 125 days after challenge administra-
tion. Even though Wve mice did not survive the tumor chal-
lenge, examination of their tumors revealed increased
numbers of CD4+ and CD19+ cells and larger necrotic
areas. The presence of both CD4+ and CD19+ lymphocytes
in these end-point tumors might involve an antibody-
dependent cell-mediated cytotoxicity of the tumor tissue.
Therefore it was assumed that tumor immunity must not
entirely rely on direct tumor cell killing [28]. Comparison
within the RM-9/mIL-7 vaccination group revealed signiW-
cant lower CD8+ T lymphocyte numbers in the tumor survi-
vors compared to the non-survivors, while CD4+ T
lymphocyte numbers did not diVer. It has been described
that IL-7 is able to alter the CD4+:CD8+ lymphocyte ratio,
which could explain our observation. However, our signiW-
cantly decrease of CD8+ cells in tumor surviving mice after
vaccination, in our model, is in contradiction with the
reported CD8+ lymphocyte increase after IL-7 administra-
tion [13]. Moreover, studies on IL-7 mediated tumor-
suppression [16, 17] indicate the importance of CD4+ T
lymphocyte recruitment, whereas CD8+ T lymphocytes
were not related to IL-7-mediated tumor-suppression.
The presence of circulating CD4+ CD25high FoxP3+ reg-
ulatory T cells (Tregs) in mice before and after administra-
tion of the subcutaneous challenge was determined in a
small number of blood samples. Only low numbers of
Tregs could be detected and, therefore, it was decided not
to examine circulating Tregs in this study. However, Tregs
might certainly be associated with T lymphocyte eVector
functions. Recently, the presence of Tregs has been associ-
ated with prostate cancer [38]. On the other hand in a
mouse prostate cancer model, Tregs were mentioned to be
common to sites of ongoing immune responses, and to be
dispensable for the induction of tumor-speciWc tolerance
[6].
Both the vaccinations with either RM-9/mGM-CSF, or
RM-9/mIL-7 were beneWcial for survival from the adminis-
tered subcutaneous tumor cell challenge. However, the
anti-tumor eVects were more evident for a subcutaneous
challenge than for an intraprostatic challenge. Since
immune surveillance in the skin is expected to be far better
than in the prostate, the intraprostatic RM-9 cell challenge
was replaced by an intraprostatic RM-9/mGM-CSF cell
challenge. It was hypothesised that mGM-CSF secretion by
the tumor could increase its surveillance. Production of
mGM-CSF by the intraprostatic tumor stimulated CD11b+
cell inWltration when compared to the parental RM-9 tumor
challenge. This inWltration was assumed to increase the
immune surveillance of the prostate, which in its turn might
be beneWcial for an anti-tumor response evoked by vaccina-
tion. This was conWrmed when a combination of RM-9/
mGM-CSF tumor challenge and RM-9/mIL-7 vaccination
resulted in larger necrotic areas in the tumor, increased
presence of CD11b+ and CD4+ T lymphocytes throughout
the tumor challenge, and signiWcantly prolonged survival
compared to RM-9/mIL-7 vaccinated mice which received
a RM-9 tumor challenge. The increased presence of
CD11b + was assumed to be the eVect of the RM-9/mGM-
CSF tumor. The CD4+ lymphocyte inWltration throughout
the tumor, together with the larger necrotic areas, was
related to the mIL-7 production by vaccine. This vaccination
eVect was no longer detectible when the tumor challenge
was administered intraprostatically. But, the combination
of the mIL-7 vaccination with an intraprostatic mGM-CSF
producing tumor challenge partly restored the vaccination
eVect and it was assumed that the observed protection could
be found in the diVerence in inWltration of CD4+ cells.
Despite the fact that some RM-9/mIL-7 vaccinated mice
did not survive the intraprostatic tumor challenge, immune
histochemistry of these tumors showed a CD4+ lymphocyte
inWltration at the rim of the tumor in case of an RM-9
tumor challenge, whereas tumors of the RM-9/mGM-CSF
challenge showed CD4+ lymphocyte inWltration through-
out the tumor. This inWltration of CD4+ lymphocytes
throughout the tumor was assumed to be the eVect of the
increased CD11+ cells that were detected in the RM-9/
mGM-CSF tumors. Altogether, this could explain the
larger necrotic areas found in these tumors and the survival
[2, 5, 7, 30–32].
Furthermore, the observed diVerence in survival
between the subcutaneous and the intraprostatic challenge
could also be an eVect of a blood-prostate-barrier, which is
assumed to restrict the passage of leukocytes for immune123
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nological attractant like GM-CSF this barrier might be bro-
ken, making the prostate better accessible. Also, recent
investigation on administration of human IL-7 in combina-
tion with GM-CSF secreting tumor cells, conWrmed the
possible immunological beneWt of the combination of IL-7
and GM-CSF [24]. This study showed for melanoma that
IL-7, when combined with GM-CSF secreting tumor cell
immunotherapy, signiWcantly prolonged the survival of the
tumor bearing mice. This enhanced anti-tumor protection
was correlated with an increased number of activated den-
dritic cells and T lymphocytes in lymphoid tissue.
Conclusion
Murine IL-7 and mGM-CSF expressed during vaccination
with a whole cell vaccine resulted in an additional immuno-
logical protection, compared to the RM-9 control vaccina-
tion, against a subcutaneously and an intraprostatically
administered RM-9 cell challenge. This enhanced protec-
tion was more evident in the skin than in the prostate. The
prostate, which is assumed to restrict the passage of leuko-
cytes for immune surveillance of the prostate, seems to be
better accessible with an immunological attractant like
GM-CSF. Furthermore, tumor immunity must not entirely
rely on direct tumor cell killing but in our model it seems to
be a combination of APCs and CD4+ lymphocytes.
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